Clinical Trial Update: Study of YK012 in Primary Membranous Nephropathy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating YK012 in primary membranous nephropathy is currently recruiting. The sponsor is Excyte Biopharma Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• YK012

Snippet

Sponsor: Excyte Biopharma Ltd | Conditions: Primary Membranous Nephropathy | Phase 1 | Status: RECRUITING